Journal of Plastic, Reconstructive & Aesthetic Surgery
Volume 61, Issue 1 , Pages 99-106 , January 2008

Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate

  • J.V. Lobato

      Affiliations

    • Servic¸o de Estomatologia, Centro Hospitalar de Vila Nova de Gaia (CHVNG), Rua Conceição Fernandes, 4434-502 Vila Nova de Gaia, Portugal
    • Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências e Tecnologias Agrárias e Agro-Alimentares (ICETA), Universidade do Porto, Campus Agrário de Vairão, Rua Padre Armando Quintas, 4485-661 Vairão, Portugal
    • ,
  • A.C. Maurício

      Affiliations

    • Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências e Tecnologias Agrárias e Agro-Alimentares (ICETA), Universidade do Porto, Campus Agrário de Vairão, Rua Padre Armando Quintas, 4485-661 Vairão, Portugal
    • Departamento de Clínicas Veterinárias, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), Universidade do Porto, Largo Professor Abel Salazar, 2, 4099-003 Porto, Portugal
    • Corresponding Author InformationCorresponding author. Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências e Tecnologias Agrárias e Agro-Alimentares (ICETA), Universidade do Porto, Campus Agrário de Vairão, Rua Padre Armando Quintas, 4485-661 Vairão, Portugal. Tel.: +351 252 660412; fax: +351 252 661780.
    • ,
  • J.M. Rodrigues

      Affiliations

    • Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências e Tecnologias Agrárias e Agro-Alimentares (ICETA), Universidade do Porto, Campus Agrário de Vairão, Rua Padre Armando Quintas, 4485-661 Vairão, Portugal
    • Servic¸o de Cirurgia Plástica e Reconstrutiva, Hospital de S. João, Av. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal
    • ,
  • M.V. Cavaleiro

      Affiliations

    • Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências e Tecnologias Agrárias e Agro-Alimentares (ICETA), Universidade do Porto, Campus Agrário de Vairão, Rua Padre Armando Quintas, 4485-661 Vairão, Portugal
    • ,
  • P.P. Cortez

      Affiliations

    • Centro de Estudos de Ciência Animal (CECA), Instituto de Ciências e Tecnologias Agrárias e Agro-Alimentares (ICETA), Universidade do Porto, Campus Agrário de Vairão, Rua Padre Armando Quintas, 4485-661 Vairão, Portugal
    • Departamento de Clínicas Veterinárias, Instituto de Ciências Biomédicas de Abel Salazar (ICBAS), Universidade do Porto, Largo Professor Abel Salazar, 2, 4099-003 Porto, Portugal
    • ,
  • L. Xavier

      Affiliations

    • Servic¸o de Hematologia, Centro Hospitalar de Vila Nova de Gaia (CHVNG), Rua Conceição Fernandes, 4434-502 Vila Nova de Gaia, Portugal
    • ,
  • C. Botelho

      Affiliations

    • Faculdade de Engenharia da Universidade do Porto (FEUP), Rua Dr. Roberto Frias, 4200-465 Porto, Portugal
    • INEB - Instituto de Engenharia Biome´dica, Laborato´rio de Biomateriais, Rua do Campo Alegre, 823, 4150-180 Porto, Portugal
    • ,
  • N. Sooraj Hussain

      Affiliations

    • Faculdade de Engenharia da Universidade do Porto (FEUP), Rua Dr. Roberto Frias, 4200-465 Porto, Portugal
    • INEB - Instituto de Engenharia Biome´dica, Laborato´rio de Biomateriais, Rua do Campo Alegre, 823, 4150-180 Porto, Portugal
    • ,
  • J.D. Santos

      Affiliations

    • Faculdade de Engenharia da Universidade do Porto (FEUP), Rua Dr. Roberto Frias, 4200-465 Porto, Portugal
    • INEB - Instituto de Engenharia Biome´dica, Laborato´rio de Biomateriais, Rua do Campo Alegre, 823, 4150-180 Porto, Portugal

Received 10 May 2006 ,Accepted 7 June 2006.

References 

  1. Mundy GR, Bertoline DR. Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol. 1986;13(3):291–299
  2. Belch AR, Bergsagel DE, Wilson K, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol. 1991;9(8):1397–1402
  3. Kyle RA, Jowsey J, Kelly PJ. Multiple myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo. N Engl J Med. 1975;293(26):1334–1338
  4. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975;50(1):29–40
  5. Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis. 2004;32(2):290–292
  6. Berenson JR. Myeloma bone disease. Best Pract Res Clin Haematol. 2005;18(4):653–672
  7. Ruggerio SL, Mekrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62:527–534
  8. Rodan GA, Fleisch HA. Bisphosphonates: mechanism of action. J Clin Invest. 1996;97(12):2692–2696
  9. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165–176
  10. Sietsema WK, Ebetino FH, Salvagno AM, et al. Antiresorptive dose–response relationship across three generations of bisphosphonates. Drugs Exp Clin Res. 1989;15(9):389–396
  11. Schenk R, Eggli P, Fleisch H, et al. Quantitative morphometric evaluation of the inhibitory activity of new amino-bisphosphonates on bone resorption in the rat. Calcif Tissue Int. 1986;38:342–349
  12. Jung A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res. 1973;11(4):269–280
  13. Coukell AJ, Markham A. Pamidronate. A review of its use in the management of osteolytic bone metastases, tumor-induced hypercalcaemia and Paget's disease of bone. Drugs Aging. 1998;12(2):149–168
  14. Hughes DE, MacDonald BR, Russel RGG, et al. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest. 1989;83(6):1930–1935
  15. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995;10(10):1478–1487
  16. Murakami H, Takahashi N, Sasaki T, et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone. 1995;17(2):137–144
  17. Sahni M, Guenther HL, Fleisch H, et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest. 1993;91(5):2004–2011
  18. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19(1):80–100
  19. Shinoda H, Adamek G, Félix R, et al. Structure–activity relationships of various bisphosphonates. Calcif Tissue Int. 1983;35(1):87–99
  20. Pereira J, Mancini I, Walker P. The role of bisphosphonates in malignant bone pain: a review. J Palliat Care. 1998;14(2):25–36
  21. Purohit OP, Radstone CR, Anthony C, et al. A randomized double-blind comparison of intravenous pamidronate and clodronate in the hypercalcemia of malignancy. Br J Cancer. 1995;72(5):1289–1293
  22. Hillner BE, Ingle JN, Chlebowski RT. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042–4057[Erratum in J Clin Oncol 2004;22(7):1351]
  23. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol. 2000;18(6):1378–1391
  24. Lacerna L, Hohneker J. Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumours. Semin Oncol. 2003;30(5 Suppl. 16):150–160
  25. Lipton A, Costa L, Ali S, et al. Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol. 2001;28(4 Suppl. 11):54–59
  26. Brincker H, Westin J, Abildgaard N, et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish–Swedish Co-operative Study Group. Br J Haematol. 1998;101(2):3280–3286
  27. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16(7):593–602
  28. Berenson JR, Vescio RA, Lee SR, et al. Phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res. 2001;7(3):478–485
  29. Van Poznak CH. The use of bisphosphonates in patients with breast cancer. Cancer Control. 2002;9(6):480–489
  30. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115–1117
  31. Vannucchi AM, Ficarra G, Antonioli E, et al. Osteonecrosis of the jaw associated with zoledronate therapy in patient with multiple myeloma. Br J Haematol. 2005;128(6):738–739
  32. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg. 2003;61(9):1104–1107
  33. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust. 2005;182(8):417–418
  34. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust. 2005;182(8):413–415
  35. Durie B, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99–102
  36. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21(22):4253–4254
  37. Robinson NA, Yeo JF. Bisphosphonates – a word of caution. Ann Acad Med Singapore. 2004;33(4):48–49
  38. Starck WJ, Epker BN. Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Oral Maxillofac Implants. 1995;10(1):74–78
  39. Melo M, Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc. 2005;71(2):111–113

PII: S1748-6815(06)00482-7

doi: 10.1016/j.bjps.2006.06.016

Journal of Plastic, Reconstructive & Aesthetic Surgery
Volume 61, Issue 1 , Pages 99-106 , January 2008

Article Tools

* Image Usage & Resolution